By Jason Methia
Scientific innovation in the life sciences industry has accelerated at a rapid pace – the FDA’s Center for Drug Evaluation and Research (CDER) approved 59 novel drugs in 2018, compared with 46 approvals in 2017, and 22 in 2016. While a major victory for patients, this innovation has introduced challenges in clinical trial execution.
With a focus on rare diseases and stratified patient populations, studies have become increasingly complex. Sponsors and CROs have widely adopted technologies to better manage this changing landscape, streamline trial processes, and accelerate end-to-end execution. Now, many clinical research sites are looking to do the same by taking advantage of new cloud-based solutions focused on their needs.